CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

GSK, Haleon and Sanofi get share price boost following Zantac news

By Jenny McCall

11:37, 6 September 2022

A image of the controversial drug Zantac.
Zantac was the world’s best-selling medicine in 1988 but worries grew about the safety of the drug - Photo: Shutterstock

Pharma giants, GlaxoSmithKline (GSK), Haleon (HLN) and Sanofi (SAN) all got a share price boost last week, after analysts at Citi bank announced that the recent ruling in the US could force many plaintiffs to abandon their claims against the companies, concerning a legal wrangle over the heartburn drug Zantac.

All three companies had previously lost a combined $31bn (£23bn) in market capitalisation in August, as investors worried about litigation. The companies are among the defendants in several lawsuits claiming that Zantac contains a cancer-causing substance called NDMA.

With that said, this downward trend was slightly reversed last week, when the trio’s share prices rose between 1-3%.

What is your sentiment on GSK?

Vote to see Traders sentiment!

GlaxoSmithKline (GSK) share price chart

Catastrophic product

“Many people consider healthcare companies to be saviours of the world, with their products helping to ease the pain of countless individuals,” Danni Hewson, financial analyst at AJ Bell, wrote in a note. “What’s often forgotten is when something goes wrong with one of their products, the fallout can be catastrophic.

“Fears of a multi-billion-dollar lawsuit for the companies involved with recalled heartburn drug Zantac have wiped billions off the value of GSK, Haleon (HLN) and Sanofi (SAN). Investors fear they will have to shell out big bucks if found guilty of failing to properly warn users about health risks, with allegations that Zantac causes cancer.”

Zantac was the world’s best-selling medicine in 1988 but worries grew about the safety of the drug. Concerns were raised in 2018, around the fact NDMA was detected in Zantac, one of the trade names of ranitidine. As a result, in September 2019, the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) ordered GSK to remove Zantac from the market.

More than 2,000 legal cases relating to Zantac have now been raised in the US.

Litigation, which commenced last month, has sparked a series of cases across several countries, with GSK facing lawsuits in the US, Canada, and Israel.


However, as GSK has now offloaded its consumer healthcare division into a new company called Haleon (HLN), will it be party to litigation over Zantac?


19,526.60 Price
-1.140% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 7.0


2,401.36 Price
-1.830% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 21:00 (UTC)
Spread 1.20


66,815.00 Price
-0.960% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00


3,492.04 Price
-1.060% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

A spokesperson for Haleon (HLN) said that the company is not party to the US litigation over Zantac.

However, analysts believe the reputational damage is just as bad.

“It’s given GSK spin-off Haleon a terrible start to life as a standalone business, with its share price having plummeted in recent days. Haleon says it isn’t party to any of the Zantac claims, yet GSK has served it with notice of potential claims in relation to liabilities connected to over-the-counter Zantac products,” Hewson said.

Zantac was originally marketed by GSK but has been sold by several other companies since the late 1990s, including Pfizer (PFE), Boehringer Ingelheim and Sanofi (SAN).

Sanofi (SAN) share price chart

A Pfizer (PFE) spokesperson said in an email to Reuters: “Pfizer, which has not sold a Zantac product in more than 15 years and did so only for a limited period of time, will continue to defend itself vigorously.”

Boehringer also responded and a spokesperson said: “The company would defend itself against any allegations."

Sanofi (SAN) issued a statement saying: “We remain confident in our legal defences and there have not been any material developments regarding the US Zantac litigation.”

The case continues.

Markets in this article

15.245 USD
-0.115 -0.750%
Pfizer Inc (Extended Hours)
30.03 USD
0.18 +0.610%
92.45 USD
-0.17 -0.180%

Rate this article

Related reading

Capital Com is an execution-only service provider. The material provided in this article is for information purposes only and should not be understood as investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents and has not been prepared in accordance with the legal requirements designed to promote investment research independence. While the information in this communication, or on which this communication is based, has been obtained from sources that believes to be reliable and accurate, it has not undergone independent verification. No representation or warranty, whether expressed or implied, is made as to the accuracy or completeness of any information obtained from third parties. If you rely on the information on this page, then you do so entirely at your own risk.

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading